Hybridoma technology applicability

More than twenty years of rodent monoclonal antibody generation by the classical hybridoma technology has yielded a number of promising therapeutic candidates and their humanization compares well to the de novo generation and characterization of human antibodies for accessing clinical applications in the coming years. 

Over the last decade, these two technologies have matured into a pattern into which most innovations needing protection can be nestled. Hybridoma technology is the simpler of the two to handle in terms of the parameters of intellectual property protection, and perhaps the less applicable to agricultural products. The technology is by now familiar to most, at least in broad outline its applicability is really confined to vertebrate species and has to... 

---